infocusdec25

In recent years, a concerning trend has emerged in the clinical research industry. Some sponsors and Contract Research Organizations (CROs) are attempting to extend site payments […]

This year's SCRS Global Site Solutions Summit celebrated the people and organizations driving clinical research forward. From groundbreaking operational solutions to transformative leadership and measurable impact on patient outcomes, the award recipients represent the best of what collaboration, innovation, and commitment can achieve. These are the organizations and leaders setting the standard for what's possible...

For over a decade, Cognizant’s Shared Investigator Platform (SIP) has transformed global clinical research, evolving from a bold vision into a trusted solution that connects thousands of sponsors, sites, and investigators. Today, SIP continues to streamline collaboration, accelerate trials, and enhance transparency to deliver better patient outcomes.

Clinical research continues to evolve toward greater connectivity and efficiency, yet study startup remains one of the most complex and time-consuming stages of a trial. Disjointed systems and communication gaps between sponsors, CROs, and research sites often lead to avoidable delays. To address these challenges, Advarra...

“It’s incredibly frustrating […] we want technology that actually improves their job”. This was shared in a recent Site Listening Session, but it’s a sentiment I’m sure many can relate to. When tools that are intended to support and accelerate are delivered without their users in mind, it’s a recipe for failure. For sites, every redundant training, missed integration opportunity, and feature that doesn’t quite work as it should, ticks away at the time that could be better spent with patients.

The landscape of oncology clinical research is rapidly evolving with the emergence of radiopharmaceutical therapies, also known as radioligand therapy (RLT). These innovative treatments represent a precision medicine approach that uses targeted radiation to treat cancer with a goal of minimizing damage to healthy tissue. However,